NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020-Reference-Cited by-同舟云学术

NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020

Published:2020-01 Issue:1 Volume:18 Page:12-22
ISSN:1540-1405
Container-title:Journal of the National Comprehensive Cancer Network
language:
Short-container-title:

Author:

Becker Pamela Sue¹,Griffiths Elizabeth A.²,Alwan Laura M.³,Bachiashvili Kimo⁴,Brown Anna⁵,Cool Rita⁶,Curtin Peter⁷,Dinner Shira⁸,Gojo Ivana⁹,Hicks Ashley¹⁰,Kallam Avyakta¹¹,Kidwai Wajih Zaheer¹²,Kloth Dwight D.¹³,Kraut Eric H.¹⁴,Landsburg Daniel¹⁵,Lyman Gary H.³,Miller Ryan¹⁶,Mukherjee Sudipto¹⁷,Patel Shiven¹⁸,Perez Lia E.¹⁹,Poust Adam²⁰,Rampal Raajit²¹,Rosovsky Rachel²²,Roy Vivek²³,Rugo Hope S.²⁴,Shayani Sepideh²⁵,Vasu Sumithira¹⁴,Wadleigh Martha²⁶,Westbrook Kelly²⁷,Westervelt Peter²⁸,Burns Jennifer²⁹,Keller Jennifer²⁹,Pluchino Lenora A.²⁹

Affiliation:

1. 1University of Washington/Seattle Cancer Care Alliance;

2. 2Roswell Park Comprehensive Cancer Center;

3. 3Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;

4. 4O'Neal Comprehensive Cancer Center at UAB;

5. 5University of Michigan Rogel Cancer Center;

6. 6The University of Texas MD Anderson Cancer Center;

7. 7UC San Diego Moores Cancer Center;

8. 8Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

9. 9The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

10. 10University of Wisconsin Carbone Cancer Center;

11. 11Fred & Pamela Buffett Cancer Center;

12. 12Yale Cancer Center/Smilow Cancer Hospital;

13. 13Fox Chase Cancer Center;

14. 14The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

15. 15Abramson Cancer Center at the University of Pennsylvania;

16. 16Vanderbilt-Ingram Cancer Center;

17. 17Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

18. 18Huntsman Cancer Institute at the University of Utah;

19. 19Moffitt Cancer Center;

20. 20University of Colorado Cancer Center;

21. 21Memorial Sloan Kettering Cancer Center;

22. 22Massachusetts General Hospital Cancer Center;

23. 23Mayo Clinic Cancer Center;

24. 24UCSF Helen Diller Family Comprehensive Cancer Center;

25. 25City of Hope National Medical Center;

26. 26Dana-Farber Cancer Institute;

27. 27Duke Cancer Center;

28. 28Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; and

29. 29National Comprehensive Cancer Network.

Abstract

Management of febrile neutropenia (FN) is an integral part of supportive care for patients undergoing cancer treatment. The NCCN Guidelines for Hematopoietic Growth Factors provide suggestions for appropriate evaluation, risk determination, prophylaxis, and management of FN. These NCCN Guidelines are intended to guide clinicians in the appropriate use of growth factors for select patients undergoing treatment of nonmyeloid malignancies. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines regarding the incorporation of newly FDA-approved granulocyte-colony stimulating factor biosimilars for the prevention and treatment of FN.

Publisher

Harborside Press, LLC

Subject

Oncology

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alternative therapy for lymphoma with febrile neutropenia using traditional Chinese medicine: A case report;EXPLORE;2024-11

2. Septic shock in the immunocompromised cancer patient: a narrative review;Critical Care;2024-08-30

3. The clinical impact of primary granulocyte-colony stimulating factor prophylaxis in children with acute lymphoblastic leukemia who underwent induction chemotherapy;Journal of Microbiology, Immunology and Infection;2024-08

4. Effectiveness of biosimilar pegfilgrastim in patients with lymphoma after high-dose chemotherapy and autologous stem cell transplantation: a real-life study;Frontiers in Hematology;2024-07-25

5. Rates of febrile neutropenia and its causes in the real world;FUTURE ONCOL;2024